Published on 04 April 2022
Biosimilar monoclonal antibodies development simplified
Author(s): Jennifer Campbell
1.456 views
Articles
Published on 22 October 2014
2013/1 GaBI Journal Table of Contents
Contents Editor's Letter Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal Letters to the Editor The ethics of biosimilars...
3.383 views
Published on 30 November 2018
Thank you to reviewers 2017
The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...
2.359 views
Published on 22 June 2021
2021/2 GaBI Journal Table of Contents
Contents Editor’s Letter What to look forward to in GaBI Journal, 2021, Issue 2 Original Research Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation Biosimilars in Saudi...
1.622 views
Meeting Report
Published on 25 March 2025
Biosimilar Red Tape Elimination Act (S.2305): weakening FDA regulatory standards for biosimilars, undermining physician confidence and jeopardizing patient health
Introduction: In the US, some biosimilars that meet additional requirements may be approved as interchangeable products. This means they can undergo pharmacy-level substitution. An online webinar titled ‘Biosimilar Red Tape Elimination...
Author(s): Michael S Reilly, Esq, Ralph D McKibbin, MD, FACP, FACG, AGAF
interchangeable biosimilar, misinformation, switch studies
124 views
Published on 30 May 2016
Thank you to reviewers 2012
The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...
2.565 views
Published on 22 October 2014
2013/2 GaBI Journal Table of Contents
Contents Editor's Letter What to look forward to in GaBI Journal, 2013, Issue 2 Editorial National and regional activities by sickness funds in Austria to encourage the rational use of...
3.516 views
Interview
Published on 15 April 2025
Turkey’s biotech manufacturing ambitions: Yerlika Biopharma’s strategic role
Abstract: Yerlika Biopharma is a pioneering biotechnology company in Turkey. Company CEO, Hasan Zeytin MD, PhD spoke to GaBI (Generics and Biosimilars Initiative) about the company’s strategic focus, Yerlika is...
Author(s): GaBI Journal Editor
biopharma, biopharmaceutical, biosimilars, biotech, Turkey
35 views
Published on 30 May 2016
Thank you to reviewers 2013
The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...
2.534 views
Published on 22 October 2014
2013/3 GaBI Journal Table of Contents
Contents Editor's Letter Latest features in GaBI Journal, 2013, Issue 3 Editorial Italy’s final position paper on biosimilars and new price and reimbursement pathway Commentary Commentary on the recommendations of...
3.034 views
Published on 30 May 2016
Thank you to reviewers 2014
The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...
2.481 views
Published on 22 August 2019
2019/2 GaBI Journal Table of Contents
Contents Editor’s Letter Unmet potential of Generics and Biosimilars to reduce healthcare costs Original Research Pricing of oral generic cancer medicines in 25 European countries; findings and implications Review Article...
2.218 views
Advertisement
